← FDA DRUG APPROVALS

FDA NDA · NDA050769

AKTIPAK

Sponsor: BIOFRONTERA

APPLICATION
NDA050769
TYPE
NDA
ORIGINAL APPROVAL
2000-11-27
LATEST ACTION
2016-09-29
ROUTE
TOPICAL
DOSAGE FORM
GEL
MARKETING STATUS
Discontinued

Products

AKTIPAK · ReferenceDiscontinued
BENZOYL PEROXIDE 5%, ERYTHROMYCIN 3% · GEL · TOPICAL

Approval history

2016-09-29Labeling · Supplement 17 · standardLetterAP
2015-03-16Manufacturing (CMC) · Supplement 16 · standardAP
2002-11-01Manufacturing (CMC) · Supplement 8 · standardAP
2002-10-23Manufacturing (CMC) · Supplement 6 · standardAP
2002-09-03Manufacturing (CMC) · Supplement 5 · standardAP
2002-08-28Manufacturing (CMC) · Supplement 7 · standardAP
2001-10-17Manufacturing (CMC) · Supplement 4 · standardAP
2001-10-17Manufacturing (CMC) · Supplement 3 · standardAP
2001-06-29Manufacturing (CMC) · Supplement 2 · standardAP
2001-03-22Manufacturing (CMC) · Supplement 1 · standardAP
2000-11-27Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →